Related Experiment Video
Updated: Jun 4, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3
Tadashi Ashizawa1, Haruo Miyata, Hidee Ishii
1Immunotherapy Division, Shizuoka Cancer Center Research Institute, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan.
Abstract:
Signal transducer and activator of transcription (STAT)3, a member of a family of DNA-binding molecules mediating numerous physiological and oncogenic signaling pathways, is a novel target in cancer cells which show high phosphorylation of STAT3. Recently, we identified a novel small-molecule inhibitor of STAT3 dimerization, STX-0119, as a cancer therapeutic. We investigated the mechanisms responsible for the antitumor activity in vitro and in vivo through numerous biochemical and biological assays. Specifically, the effects of STX-0119 on target genes (c-myc, cyclin D1, survivin) and apoptosis induction were analyzed in tumors treated with STX-0119 in vivo. STX-0119 showed strong growth-inhibitory activity against a broad range of hematological cancer cell lines, particularly lymphomas. STX-0119 suppressed the growth of SCC3 cells, a human lymphoma cell line with highly activated STAT3, through apoptosis and down-regulation of STAT3 targets such as c-myc, cyclin D1, survivin and Bcl-xL. Notably, Tyr-705-phosphorylated STAT3 up-regulation was not significantly suppressed by STX-0119, as opposed to other STAT3 inhibitors. STX-0119 demonstrated potent antitumor effects in vivo in SCC3-bearing nude mice by way of the down-regulation of STAT3 target genes and induction of apoptosis in the tumors. Thus, STX-0119 may be a new type of STAT3 inhibitor exhibiting strong antitumor activity.
Insights
A novel small-molecule inhibitor, STX-0119, effectively targets Signal transducer and activator of transcription (STAT)3 dimerization, showing potent antitumor activity against hematological cancers by inducing apoptosis and down-regulating key target genes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Signal transducer and activator of transcription (STAT)3 is a key mediator in physiological and oncogenic pathways.
- High STAT3 phosphorylation is observed in various cancer cells, making it a significant therapeutic target.
- STAT3 dimerization inhibitors represent a novel approach to cancer treatment.
Purpose of the Study:
- To investigate the antitumor mechanisms of STX-0119, a novel small-molecule inhibitor of STAT3 dimerization.
- To evaluate the in vitro and in vivo efficacy of STX-0119 against hematological cancer cell lines, particularly lymphomas.
- To analyze the effects of STX-0119 on STAT3 target genes and apoptosis induction.
Main Methods:
- Biochemical and biological assays were employed to assess STX-0119's activity.
- In vitro studies involved various hematological cancer cell lines, including SCC3 lymphoma cells.
- In vivo studies utilized SCC3-bearing nude mice to evaluate antitumor effects.
Main Results:
- STX-0119 demonstrated significant growth-inhibitory activity across a broad spectrum of hematological cancer cell lines, with notable efficacy in lymphomas.
- In SCC3 cells, STX-0119 suppressed growth via apoptosis induction and down-regulation of STAT3 targets (c-myc, cyclin D1, survivin, Bcl-xL).
- Unlike other inhibitors, STX-0119 did not significantly suppress Tyr-705-phosphorylated STAT3, suggesting a distinct mechanism of action.
Conclusions:
- STX-0119 exhibits potent antitumor effects in vivo and in vitro, particularly in hematological malignancies.
- The compound acts by down-regulating STAT3 target genes and inducing apoptosis in tumor cells.
- STX-0119 represents a new class of STAT3 inhibitors with promising therapeutic potential for cancer treatment.
